What are the specific drugs in COVID-19?
Drugs commonly used to treat novel coronavirus infection include Lianhua Qingwen Capsule and ibuprofen. So today, Xiaobian is here to sort out what the leading stocks of COVID-19's specific drugs are. Let's take a look!
Guangshengtang 3436
The main business of Fujian Guangshengtang Pharmaceutical Co., Ltd. is the research and development, production and sales of nucleoside anti-hepatitis B virus drugs; The company's main products are anti-HBV drugs, liver protection drugs, digestive system drugs, respiratory system drugs, cardiovascular drugs and medical inspection services;
At present, the company is a domestic pharmaceutical enterprise focusing on the field of liver health, and it is the only pharmaceutical enterprise in China that has four major clinical preferred drugs for anti-HBV: adefovir dipivoxil, lamivudine, entecavir and tenofovir.
China Resources Shuanghe 662
China Resources Shuanghe Pharmaceutical Co., Ltd. is mainly engaged in chronic disease business, specialist business and infusion business. The main products include compound reserpine triamcinolone acetonide tablets (No.), citicoline sodium tablets (Nobuyi), amlodipine besylate tablets (Astrid), magnesium valproate sustained-release tablets (Shentai), gliquidone tablets (Tangshiping), soft bags (including straight soft) and sealed polypropylene infusion.
China Resources Shuanghe announced that it has signed the Strategic Cooperation Agreement and the Framework Agreement on the Entrusting Processing and Production of Azif Tablets with real creatures, and will be entrusted to process and produce Azif Tablets.
minova 63538
Ningbo minova pharmaceutical co., ltd. is mainly engaged in the research and development, production and sales of characteristic raw materials (including intermediates) and finished drugs, and its main categories include cardiovascular drugs and gastrointestinal drugs.
the company's main products are valsartan, losartan, perindopril, rosuvastatin, atorvastatin, clopidogrel and esomeprazole, ticlopidine, duloxetine and mirtazapine.
The company's important API production bases are all national high-tech enterprises, and they have established strict quality management system and EHS management system, and passed GMP certification in regulated markets such as the European Union, China and Japan. The company is one of the top 1 pharmaceutical internationalization enterprises in China, a high-quality supplier and partner in the international market (ranked in the top 6). Its core products cover cardiovascular, central nervous system, gastrointestinal tract and other therapeutic fields, and it is one of the enterprises that export the most varieties of raw materials with European characteristics in China.
Xinhua Pharmaceutical 756
Shandong Xinhua Pharmaceutical Co., Ltd. is mainly engaged in developing, manufacturing and selling chemical raw materials, preparations and chemical products; The company's main products are antipyretic and analgesic raw materials, tablets, injections, capsules and pharmaceutical intermediates.
the company has the advantage of technological innovation, and is now a high-tech enterprise, a key high-tech enterprise of the national torch plan, a backbone enterprise of the biomedical industrial base of the national torch plan, a national enterprise technology center and an enterprise Post-Doctoral Research Center. "Construction and scale development of green caffeine preparation system based on key industrialization technologies" won the second prize of Shandong Science and Technology Progress in 218. In the first half of the year, 1 patents were granted. The company was publicized as "Shandong Technological Innovation Demonstration Enterprise" and was rated as an advanced unit of talent work in Shandong.